Immunitybio Announces Results Of Anktiva Combined With Checkpoint Inhibitors In Non-Small Cell Lung Cancer; Schedules Meeting To Discuss Registration Path For ANKTIVA In Lung Cancer With FDA
Portfolio Pulse from Benzinga Newsdesk
ImmunityBio's QUILT 3.055 trial for ANKTIVA in combination with checkpoint inhibitors shows promising results in NSCLC patients, nearly doubling median overall survival compared to standard chemotherapy. The trial's success across PD-L1 negative and positive participants highlights ANKTIVA's potential as an immune cell enhancer. A meeting with the FDA is scheduled for June to discuss ANKTIVA's registration for NSCLC. Additionally, a $100 million non-dilutive cash infusion upon ANKTIVA's approval will boost the company's cash reserves to $240 million, aiding the launch in NMIBC and supporting its role in future clinical trials.
April 25, 2024 | 6:57 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ImmunityBio's ANKTIVA demonstrates significant potential in NSCLC, with FDA discussions planned and a substantial financial boost expected upon approval.
The positive trial results for ANKTIVA in NSCLC patients, combined with the scheduled FDA meeting and the anticipated $100 million cash infusion upon approval, signal a strong potential for ImmunityBio's stock. The trial's success in improving median overall survival rates and the drug's potential across multiple tumor types could significantly impact the company's valuation and investor interest.
CONFIDENCE 90
IMPORTANCE 95
RELEVANCE 100